Time to healing is critical in order to avoid hypertrophic scarring12. Cells isolated with ReCell from the dermal-epidermal junction are able to rapidly proliferate and migrate within the wound bed to provide an even, confluent, cell cover across the wound bed that improves healing time.
Research by Navarro et. al.9 demonstrated increased epidermal thickness, confluence, keratin cysts and blood vessels on histological analysis of full-thickness wounds treated with ReCell treated areas compared to those treated with control models. Wounds sprayed with the processed ReCell suspension have demonstrated faster and better quality of epithelialisation than control wounds1.
A number of studies have demonstrated that autologous cells delivered via the ReCell suspension result in a more reliable take, more rapid healing and improved scar quality in comparison to either autologous or allogeneic cultured sheet technologies thus delivering improved and more reliable wound adherence.2,3,4,5
Magnusson et al.6 reported results of a double-blind randomised trial which demonstrated significantly accelerated epithelialisation and improved maturation in partial thickness wounds seeded with the epidermal cell suspension in comparison to control wounds treated with other methods.
Areas of hypo- and hypertrophic pigmentation remain a significant issue to patients. Significantly improved pigmentation in treatment areas, based on patient as well as clinician ratings, have resulted with the use of ReCell cell suspension in a variety of different indications including acute burns, burn scar revision, hypo or hyper pigmented areas and patients suffering from Vitiligo. 7,8,9,10,11
Autologous, Site matched
Replacing "like-with-like" tissue ensures optimised outcomes. In an analysis of 29 cases treated with ReCell (utilising site-matched cell suspensions) in comparison to other standardly utilised treatments,
The ReCell-treated areas yielded significantly improved outcomes in glabrous skin injuries, mitigated contractures, fissures and hyperkeratosis. ReCell treated areas yielded tissue with smoother contours, texture and sensitivity matching, and preserved and site-matched pigmentation. For those treated regions in which ReCell was used in combination with mesh skin grafts (i.e., deep burns) a significant decrease in visual mesh pattern was apparent.12
Research & Publications
A complete list of studies and publication on our spray technology can be found on the ReCell website.
Avita Medical is continuing its ongoing research, working closely with the McComb Foundation. The McComb Foundation (Inc.) is a research based organisation that was established in 1999 with the aim of entering into collaborative research programs worldwide as well as offering research opportunities to highly skilled scientists. The McComb Foundation has entered into an agreement that gives the company the exclusive global commercialisation rights to its technology and a first right of refusal over any future cellular and tissue engineered technology.
The company is adding value to the basic science work of the McComb Foundation through its own research, development and clinical trial programme.